Product guide · Restricted substance
Thaiger BPC-157 5mg TB-500 5 mg Peptide Complex
Peptide product from Thaiger Pharma. This guide sets out what the manufacturer states about the composition of Thaiger BPC-157 5mg TB-500 5 mg Peptide Complex, what independent research says about its main ingredients, and the safety and regulatory points that apply. It contains substances that are not authorised as food or medicine in the EU. This guide is educational: it does not recommend use and gives no directions for use.
Back to the product- Named ingredients
- 2
- Amounts stated
- All
- Status
- Restricted substance
- Evidence summaries
- 2
Overview
Manufacturer informationIngredients & composition
Manufacturer information| Ingredient | Amount |
|---|---|
| BPC-157 | 5 mg (as stated in the product title) |
| TB-500 | 5 mg (as stated in the product title) |
Scientific background
Independent researchBPC-157
BPC-157 ("body protection compound") is a synthetic peptide of 15 amino acids, derived from a sequence of a protein in human gastric juice. It is studied for tissue healing1.
TB-500 (thymosin β4 fragment)
TB-500 is marketed as a synthetic version or fragment of thymosin β4 (Tβ4), a naturally occurring protein involved in cell migration and tissue repair2.
Research evidence
Independent researchBPC-157
Most research on BPC-157 consists of animal and cell studies reporting effects on tendon, ligament, muscle and gut healing13.
A 2026 systematic review found only three small human studies: a retrospective study of knee injections, a pilot study in interstitial cystitis and a two-person intravenous safety study. All were of poor methodological quality, and the overall certainty of evidence was very low45.
TB-500 (thymosin β4 fragment)
Thymosin β4 accelerated dermal healing in animal models and in phase 2 trials in patients with pressure ulcers, venous stasis ulcers and epidermolysis bullosa wounds2. Those trials used the full natural protein in clinical settings, not TB-500 products.
Evidence limitations
Independent researchThe studies summarised in this guide examined single ingredients. No published study has tested this product or this combination of ingredients.
BPC-157
Reviewers conclude that well-designed human trials are needed to assess safety and efficacy, and that BPC-157 should not be used clinically in humans outside ethically approved, regulated trials43.
TB-500 (thymosin β4 fragment)
There are no published controlled human trials of TB-500 products for muscle or tendon injuries or performance. Reviewers describe a "gray market" of unapproved peptides sold directly to consumers outside regulatory oversight, with uncertain purity and safety6.
Safety & potential risks
Independent researchBPC-157
Human safety data are minimal. Reviewers highlight risks from unregulated manufacturing and contamination, and unknown clinical safety7. The US FDA placed BPC-157 among bulk substances that may present significant safety risks in compounding, citing possible immunogenicity and peptide impurities8.
TB-500 (thymosin β4 fragment)
Human safety data for TB-500 products are lacking6.
Regulatory status
Contains a peptide that is not authorised as food (including food supplements) or as a medicinal product in the EU. No dosing information for human use is provided.
Scientific references
- Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel). 2025;18:185. PubMed 40005999
- Kleinman HK, Sosne G. Thymosin β4 promotes dermal healing. Vitam Horm. 2016;102:251-275. PubMed 27450738
- McGuire FP, Martinez R, Lenz A, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18:611-619. PubMed 40789979
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92. PubMed 42885452
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27:8-13. PubMed 34324435
- Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56:1921-1935. PubMed 41966639
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21:485-495. PubMed 40756949
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (lists BPC-157). Source
- Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union. Source
- Regulation (EU) 2015/2283 on novel foods. Official Journal of the European Union. Source
- World Anti-Doping Agency. The Prohibited List (current edition). Source
Sources checked against PubMed, Crossref or the official publisher on 2026-11-04. Manufacturer information is taken from the product's own data and has not been independently tested.
The product
Thaiger BPC-157 5mg TB-500 5 mg Peptide Complex
€72,90